Srs Capital Advisors, Inc. Vaxcyte, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 52 shares of PCVX stock, worth $6,008. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52Holding current value
$6,008% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
286Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.15 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.13 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$1.02 Billion0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$948 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$531 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.85B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...